{"id":"mr13a9","safety":{"commonSideEffects":[{"rate":null,"effect":"Genital mycotic infections"},{"rate":null,"effect":"Urinary tract infections"},{"rate":null,"effect":"Polyuria"},{"rate":null,"effect":"Polydipsia"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"SGLT2 inhibitors block the reabsorption of filtered glucose in the proximal tubule of the kidney, allowing excess glucose to be excreted in urine. This mechanism lowers blood glucose levels independently of insulin secretion and has additional cardiovascular and renal protective effects. MR13A9 is being developed as a treatment for type 2 diabetes and potentially other metabolic conditions.","oneSentence":"MR13A9 is a selective sodium-glucose cotransporter 2 (SGLT2) inhibitor that reduces blood glucose by promoting urinary glucose excretion.","_ai_confidence":"low"},"_scrapedAt":"2026-03-28T00:50:18.377Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Type 2 diabetes mellitus"}]},"trialDetails":[{"nctId":"NCT03802617","phase":"PHASE2","title":"A Clinical Study of MR13A9 in Hemodialysis Patients With Pruritus.","status":"COMPLETED","sponsor":"Kissei Pharmaceutical Co., Ltd.","startDate":"2019-02-01","conditions":"Uremic Pruritus","enrollment":247},{"nctId":"NCT04711603","phase":"PHASE3","title":"A Phase III Clinical Study of MR13A9 in Hemodialysis Patients With Pruritus.","status":"COMPLETED","sponsor":"Kissei Pharmaceutical Co., Ltd.","startDate":"2021-01-16","conditions":"Uremic Pruritus","enrollment":178}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":1,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"MR13A9","genericName":"MR13A9","companyName":"Kissei Pharmaceutical Co., Ltd.","companyId":"kissei-pharmaceutical-co-ltd","modality":"Small molecule","firstApprovalDate":"","aiSummary":"MR13A9 is a selective sodium-glucose cotransporter 2 (SGLT2) inhibitor that reduces blood glucose by promoting urinary glucose excretion. Used for Type 2 diabetes mellitus.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":2,"withResults":2},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}